Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dexcom (DXCM)

Dexcom CEO Kevin Sayer takes medical leave; COO Jacob Leach named interim CEO

Neutral Impact 4 of 5 leadership Written later

Dexcom said CEO and Chairman Kevin R. Sayer is on a temporary medical leave effective September 14, 2025. The board named President and COO Jacob S. Leach as interim principal executive officer and Lead Independent Director Mark Foletta as interim chairman; neither will receive extra pay for the interim roles.

Key points

  • Kevin R. Sayer, CEO and Chairman, began a temporary medical leave effective September 14, 2025.
  • Jacob S. Leach, President and Chief Operating Officer, is interim principal executive officer in addition to his current duties.
  • Mark Foletta, Lead Independent Director, is interim chairman of the Board.
  • Leach and Foletta will not receive additional compensation for the interim appointments.

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECSep 15, 2025, 7:30 PM ET
Accession number0001093557-25-000257

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.